Study summary
Immunotherapy alone cleared every dMMR rectal cancer that finished treatment
92%free of recurrence at 2 years
What was tested
Six months of dostarlimab, a PD-1 immunotherapy, before planned surgery for stage I to III dMMR tumors. People whose tumor disappeared could skip surgery. No comparison group.
What they found
- All 49 people with dMMR rectal cancer who completed treatment had a complete clinical response and skipped surgery.
- Recurrence-free survival at 2 years was 92% across all 117 people.
- Side effects were mostly mild.
What it means
For dMMR rectal cancer, immunotherapy may replace surgery, radiation and chemotherapy.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.